Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II???Multi-center, Clinical Study

Next Previous
Trial Profile

Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II???Multi-center, Clinical Study

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Rivoceranib (Primary) ; Temozolomide (Primary)
  • Indications Neuroblastoma
  • Focus Therapeutic Use

Most Recent Events

  • 17 Apr 2025 The protocol has been amended to addition in number of arms, interventional study model as sequential assignment and study phase.
  • 17 Apr 2025 Planned number of patients changed from 62 to 125.
  • 19 Sep 2023 Planned End Date changed from 30 Aug 2023 to 30 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top